Abstract: A method of spectral analyzing with a color camera is provided, and the method includes: calibrating a color camera to obtain a quantum efficiency database of the color camera; shooting a detection area with the color camera, the detection area including at least one object, to obtain the color content data of the at least one object; and comparing the color content data to the quantum efficiency database to analyze the at least one object.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

Abstract: Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1, 5-alpha]benzimidazole compound and the preparation method and intermediate thereof.

Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.

Abstract: Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1,5-alpha]benzimidazole compound and a preparation method and intermediate thereof.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

Abstract: A natural composition that includes C. osmophloeum and C. pinnatifida. The C. osmophloeum is an aqueous extract of Cinnamomum osmophloeum leaves. The Crataegus pinnatifida is an aqueous extract of C. pinnatifida fruit. The weight ratio of the C. osmophloeum to the C. pinnatifida is 1:0.05-2, the preferred ratio is 1:0.5-1.5, and the optimal ratio is 1:0.9-1.1. The pharmaceutical composition has an ?-glucosidase inhibition effect. The natural composition can further inhibit ?-amylase to regulate the absorption of blood glucose and carbohydrate.

Abstract: A method for manufacturing a nylon 66 hollow fiber includes steps as follows. A plurality of nylon 66 particles are provided. A melting step is provided, wherein the nylon 66 particles are melted so as to form a spun liquid. A fiber spitting step is provided, wherein the spun liquid goes through a hollow spinneret plate so as to form hollow nascent fibers. An evacuating step is provided, wherein the hollow nascent fibers are preliminarily solidified so as to form hollow half-solidified fibers. A cooling step is provided, wherein the hollow half-solidified fibers are cooled and solidified so as to form solidified fibers. A collecting and oiling step is provided. A drawing step is provided. A winding step is provided so as to obtain the nylon 66 hollow fiber.

Abstract: A modular apparatus of fuel cell system includes a start burner, a reformer, an after-burner, and a heat exchanger. The start burner, the reformer, the after-burner, and the heat exchanger are disposed in a chamber. The start burner is surrounded by the reformer, and the after-burner is disposed on the start burner and surrounds the reformer. The heat exchanger surrounds the after-burner and the reformer.

Abstract: A mechanism is provided for enhancing security access to a data processing system. Responsive to authenticating a first factor of the multi-factor authentication by matching a scanned fingerprint/thumbprint of a user to at least one previously scanned fingerprint/thumbprint in a set of previously scanned fingerprints/thumbprints, a determination is made as to whether a touch pressure level exerted by the user on a touch pressure sensor associated with the data processing system matches at least one previously stored touch pressure level in a set of previously stored touch pressure levels. Responsive to matching the touch pressure level exerted by the user to a previously stored touch pressure level in the set of previously stored touch pressure levels, a second factor of the multi-factor authentication is authenticated. Access is then granted for the user to the data processing system.

Abstract: A hydrogen circulation system for fuel cell includes a hydrogen supply pipeline, a return pipeline, a buffer tank, an ejector, a differential pressure valve, a solenoid valve, and a controller. The return pipeline connects a hydrogen outlet of a fuel cell stack and the hydrogen supply pipeline. The buffer tank is installed at the return pipeline. The ejector is installed at the hydrogen supply pipeline for connecting the buffer tank. The differential pressure valve is between a hydrogen source and the ejector for adjusting a pressure in the hydrogen supply pipeline based on a pressure difference between an anode inlet and a cathode inlet of the fuel cell stack. The solenoid valve is installed at the return pipeline between the buffer tank and the hydrogen outlet. According to an output voltage or a load of the fuel cell stack, a switch of the solenoid valve is controlled by the controller.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

Abstract: The present invention provides a pyrimidine derivative and a use thereof. The pyrimidine derivative is the compound shown in formula I or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein, R1, R2, R3, R4 and R5 are, for example, as defined in the specification. The compound can act as an ALK inhibitor, and is for preparing an anti-tumor medicament for suppressing an anaplastic lymphoma kinase.

Abstract: Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1, 5-alpha]benzimidazole compound and the preparation method and intermediate thereof.

Abstract: The present disclosure provides a communication method, a communication system, a resource pool management system, a switch device and a control device in a Software-Defined Network (SDN).

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

Abstract: Disclosed is a series of analogs of 4H-pyrazolo[1,5-?]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.